Furthermore, TRPV1 antagonists have therapeutic indications in the treatment of DM2, because of their dual effects as insulin sensitizers and secretagogues32 and as anti-obesity drugs33 studies are however necessary to determine the implication of TRPV1 in osteoclastogenesis induced by DM2. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.